Equity Overview
Price & Market Data
Price: $15.83
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $862,625,792
Volume: 0
Performance Metrics
1 Week: 15.38%
1 Month: 3.80%
3 Months: -18.06%
6 Months: -30.08%
1 Year: -24.15%
YTD: -17.42%
Company Details
Employees: 108
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Netherlands
Details
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.